Perioperative and Postoperative Therapies for Resectable Lung Cancer

Surgical outcomes are less than ideal and recent data will be reviewed on optimal combination of immunotherapy with surgery to improve those outcomes.

It is imperative for physicians managing patients with early stage lung cancer to be aware of the data supporting the very new standard of care using pre-, post-, and perioperative immunotherapy to support their practice decisions. Attendees need to determine when and how the latest science will affect their day-to-day practice, and thus be able to narrow competency gaps in the management of early stage lung cancer. Attendees should use the information provided in this session to work with their medical and surgical oncology colleagues to optimally manage surgically resectable lung cancer. The role of radiation in this setting needs further study to optimally integrate into this paradigm.

Completely surgically resected non-small cell lung cancer, even with adjuvant chemotherapy, resulted in approximately 50% five-year survival, with many patients relapsing and dying in spite of complete resections. In this session, we will review the current data for the use of immunotherapy before and after surgery, learn how to best apply these data to attendee clinical practice and review the questions being addressed in current clinical trials.

Target Audience

This meeting is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists and pulmonologists.

Learning Objectives

Upon completion of this activity, participants should be able to do the following:

  • Understand the current data supporting the use of pre-, post-, and perioperative chemo/immunotherapy.
  • Apply these data to their practices in collaboration with other specialties.
  • Describe the current research questions being addressed in this area.
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.50 Certificate of Attendance
    This activity was designated for 1.50 AMA PRA Category 1 Credit™.
Course opens: 
12/03/2023
Course expires: 
12/02/2025
Cost:
$0.00
Part of: 
2023 Multidisciplinary Thoracic Cancers Symposium onDemand
Rating: 
0

Moderator:

  • David Carbone, MD, PhD

Speakers:

  • Marina Garassino, MD
  • Neel CChudgar, MD
  • Jeremy Brownstein, MD

 

Faculty:
A list of all meeting faculty and Individual presenter disclosures are linked to their names in the Schedule of Events.

Planning Committee:
A list of all meeting planning committee members and their individual disclosures can be found on the Planning Committee website page.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.50 Certificate of Attendance
    This activity was designated for 1.50 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.